- Home
- Left Ventricular Assist Device Lvad Market
Global Left Ventricular Assist Device (LVAD) Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-352 | No of pages: 489 | Format:
Global left ventricular assist device (LVAD) market is projected to register a CAGR of 9.6% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029
Market Segmentation:
Global Left Ventricular Assist Device (LVAD) Market, By Product Type (Heart Pump, Controller, Batteries, Wires), Therapy (Bridge-To-Transplant (BTT) Therapy, Destination Therapy, Bridge-To-Candidacy (BTC) Therapy, Bridge-To-Recovery (BTR) Therapy), Age Group (Adult, Pediatric), Indication (Congestive Heart Failure, Congenital Heart Disease, Myocarditis, Cardiac Arrest, Familial Arrhythmias and Arrhythmic, Cardiomyopathies, Advanced Heart Failure, Others), Generation (Second Generation Devices, Third Generation Devices, First Generation Devices), Durability (Long-Term, Intermediate-Term, Short-Term), Design (Axial, Centrifugal), Pulse Type (Nonpulsatile, Pulsatile), End User (Hospitals, Cardiac Cath Laboratories, Specialty Clinics, Others), Distribution Channel (Direct Tender, Retail Sales, Others), Country (U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Ireland, Rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel and Rest of Middle East And Africa, Brazil, Argentina and Rest of South America) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the global left ventricular assist device (LVAD) market are:
Increasing geriatric population along with rising prevalence of cardiac diseases
Presence of favorable reimbursement policies
Market Players:
The key market players for global left ventricular assist device (LVAD) market are listed below:
Abbott
Evaheart, Inc
Saft (A Subsidiary of TotalEnergies)
ABIOMED
Berlin Heart
CorWave SA
Jarvik Heart, Inc.
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.10 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S
4.3 INDUSTRIAL INSIGHTS:
5 GLOBAL LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: REGULATIONS
5.1 REGULATION IN U.S.
5.1.1 GUIDELINES-
5.2 REGULATION IN EUROPE
5.2.1 GUIDELINES FOR THE MANUFACTURERS:
5.3 REGULATION IN CANADA
5.3.1 GUIDELINES FOR THE MANUFACTURERS:
5.4 REGULATION IN MEXICO
5.4.1 GUIDELINES FOR THE MANUFACTURERS:
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING GERIATRIC POPULATION ALONG WITH RISING PREVALENCE OF CARDIAC DISEASES
6.1.2 PRESENCE OF FAVOURABLE REIMBURSEMENT POLICIES
6.1.3 CHANGING LIFESTYLE TRIGGERS THE DEVELOPMENT OF CARDIOVASCULAR DISEASES
6.2 RESTRAINTS
6.2.1 HIGH COST OF LVAD IMPLANTATION AND TREATMENT
6.2.2 COMPLICATIONS AND RISKS ASSOCIATED WITH LVAD
6.3 OPPORTUNITIES
6.3.1 INCREASE IN HEALTHCARE EXPENDITURE
6.3.2 INCREASE IN MINIMALLY INVASIVE PROCEDURE
6.3.3 INCREASING SHORTAGE OF ORGAN DONORS
6.3.4 TECHNOLOGICAL ADVANCEMENTS IN LEFT VENTRICULAR ASSIST DEVICES
6.4 CHALLENGES
6.4.1 ONGOING COVID-19
6.4.2 INCREASE IN PRODUCT RECALL
7 GLOBAL LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 HEART PUMP
7.3 CONTROLLER
7.4 BATTERIES
7.4.1 RECHARGEABLE
7.4.2 NON-RECHARGEABLE
7.5 WIRES
8 GLOBAL LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY
8.1 OVERVIEW
8.2 BRIDGE-TO-TRANSPLANT (BTT) THERAPY
8.2.1 HEART PUMP
8.2.2 CONTROLLER
8.2.3 BATTERIES
8.2.4 WIRES
8.3 DESTINATION THERAPY
8.3.1 HEART PUMP
8.3.2 CONTROLLER
8.3.3 BATTERIES
8.3.4 WIRES
8.4 BRIDGE-TO-CANDIDACY (BTC) THERAPY
8.4.1 HEART PUMP
8.4.2 CONTROLLER
8.4.3 BATTERIES
8.4.4 WIRES
8.5 BRIDGE-TO-RECOVERY (BTR) THERAPY
8.5.1 HEART PUMP
8.5.2 CONTROLLER
8.5.3 BATTERIES
8.5.4 WIRES
9 GLOBAL LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY AGE GROUP
9.1 OVERVIEW
9.2 ADULT
9.2.1-39 YEARS
9.2.2-59 YEARS
9.2.3-79 YEARS
9.2.4 ABOVE 80 YEARS
9.3 PEDIATRIC
10 GLOBAL LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY GENERATION
10.1 OVERVIEW
10.2 SECOND GENERATION DEVICES
10.3 THIRD GENERATION DEVICES
10.4 FIRST GENERATION DEVICES
11 GLOBAL LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY DESIGN
11.1 OVERVIEW
11.2 AXIAL
11.3 CENTRIFUGAL
12 GLOBAL LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION
12.1 OVERVIEW
12.2 CONGESTIVE HEART FAILURE
12.2.1 HEART PUMP
12.2.2 CONTROLLER
12.2.3 BATTERIES
12.2.4 WIRES
12.3 CONGENITAL HEART DISEASE
12.3.1 HEART PUMP
12.3.2 CONTROLLER
12.3.3 BATTERIES
12.3.4 WIRES
12.4 MYOCARDITIS
12.4.1 HEART PUMP
12.4.2 CONTROLLER
12.4.3 BATTERIES
12.4.4 WIRES
12.5 CARDIAC ARREST
12.5.1 HEART PUMP
12.5.2 CONTROLLER
12.5.3 BATTERIES
12.5.4 WIRES
12.6 FAMILIAL ARRHYTHMIAS AND ARRHYTHMIC CARDIOMYOPATHIES
12.6.1 HEART PUMP
12.6.2 CONTROLLER
12.6.3 BATTERIES
12.6.4 WIRES
12.7 ADVANCED HEART FAILURE
12.7.1 HEART PUMP
12.7.2 CONTROLLER
12.7.3 BATTERIES
12.7.4 WIRES
12.8 OTHERS
13 GLOBAL LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY DURABILITY
13.1 OVERVIEW
13.2 LONG-TERM
13.3 INTERMEDIATE-TERM
13.4 SHORT-TERM
14 GLOBAL LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY PULSE TYPE
14.1 OVERVIEW
14.2 NONPULSATILE
14.3 PULSATILE
15 GLOBAL LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITAL
15.3 CARDIAC CATH LABORATORIES
15.4 SPECIALTY CLINICS
15.5 OTHERS
16 GLOBAL LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
16.4 OTHERS
17 GLOBAL LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY REGION
17.1 OVERVIEW
17.2 NORTH AMERICA
17.2.1 U.S.
17.2.2 CANADA
17.2.3 MEXICO
17.3 EUROPE
17.3.1 GERMANY
17.3.2 FRANCE
17.3.3 U.K.
17.3.4 ITALY
17.3.5 RUSSIA
17.3.6 SPAIN
17.3.7 TURKEY
17.3.8 NETHERLANDS
17.3.9 SWITZERLAND
17.3.10 BELGIUM
17.3.11 IRELAND
17.3.12 REST OF EUROPE
17.4 ASIA-PACIFIC
17.4.1 JAPAN
17.4.2 CHINA
17.4.3 SOUTH KOREA
17.4.4 INDIA
17.4.5 AUSTRALIA
17.4.6 SINGAPORE
17.4.7 THAILAND
17.4.8 MALAYSIA
17.4.9 PHILIPPINES
17.4.10 INDONESIA
17.4.11 REST OF ASIA-PACIFIC
17.5 MIDDLE EAST & AFRICA
17.5.1 SAUDI ARABIA
17.5.2 SOUTH AFRICA
17.5.3 U.A.E.
17.5.4 EGYPT
17.5.5 ISRAEL
17.5.6 REST OF MIDDLE EAST & AFRICA
17.6 SOUTH AMERICA
17.6.1 BRAZIL
17.6.2 ARGENTINA
17.6.3 REST OF SOUTH AMERICA
18 GLOBAL LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: GLOBAL
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
18.3 COMPANY SHARE ANALYSIS: EUROPE
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 ABIOMED
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.1.5.1 FDA APPROVAL
20.1.5.2 FDA APPROVAL
20.2 ABBOTT
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.2.5.1 SUPPLY INCREMENT
20.2.5.2 BREAK THROUGH DEVICE DESIGNATION
20.3 BERLIN HEART
20.3.1 COMPANY SNAPSHOT
20.3.2 COMPANY SHARE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENT
20.3.4.1 PRODUCT APPROVAL
20.4 SAFT (A SUBSIDIARY OF TOTALENERGIES)
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENT
20.4.5.1 PARTNERSHIP
20.5 JARVIK HEART, INC.
20.5.1 COMPANY SNAPSHOT
20.5.2 COMPANY SHARE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENT
20.5.4.1 FDA APPROVAL
20.6 CORWAVE SA
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.6.3.1 EXPANSION
20.7 EVAHEART, INC
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.7.3.1 PRODUCT TRIAL
21 QUESTIONNAIRE
22 RELATED REPORTS
Segmentation
Short Description
Global Left Ventricular Assist Device (LVAD) Market, By Product Type (Heart Pump, Controller, Batteries, Wires), Therapy (Bridge-To-Transplant (BTT) Therapy, Destination Therapy, Bridge-To-Candidacy (BTC) Therapy, Bridge-To-Recovery (BTR) Therapy), Age Group (Adult, Pediatric), Indication (Congestive Heart Failure, Congenital Heart Disease, Myocarditis, Cardiac Arrest, Familial Arrhythmias and Arrhythmic, Cardiomyopathies, Advanced Heart Failure, Others), Generation (Second Generation Devices, Third Generation Devices, First Generation Devices), Durability (Long-Term, Intermediate-Term, Short-Term), Design (Axial, Centrifugal), Pulse Type (Nonpulsatile, Pulsatile), End User (Hospitals, Cardiac Cath Laboratories, Specialty Clinics, Others), Distribution Channel (Direct Tender, Retail Sales, Others), Country (U.S., Canada, Mexico, Germany, France, United Kingdom, Italy, Russia, Spain, Turkey, Netherlands, Switzerland, Belgium, Ireland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Philippines, Indonesia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, South Africa, U.A.E., Egypt, Israel, rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Definition:
A left ventricular assist device (LVAD) is a mechanical pump that is implanted in patients with heart failure. It helps the bottom left chamber of your heart (left ventricle) pump blood out of the ventricle to the aorta and the rest of the body.
A left ventricular assist device (LVAD) is a pump that we use for patients who have reached end-stage heart failure. The LVAD is surgically implanted, a battery-operated, mechanical pump, which then helps the left ventricle (main pumping chamber of the heart) pump blood to the rest of the body. LVADs can be used as:
Bridge-to-transplant therapy: This is a life-saving therapy for patients awaiting a heart transplant. Patients use the LVAD until a heart becomes available. In some cases, the LVAD is able to restore the failing heart, eliminating the need for a transplant.
Destination therapy: Some patients are not candidates for heart transplants. In this case, patients can receive long-term treatment using an LVAD, which can prolong and improve patients' lives.
The high prevalence of cardiovascular diseases, increasing technological advancement, and rising healthcare expenditure are also propelling the growth of the global left ventricular assist device (LVAD) market.
Market Segmentation:
Global left ventricular assist device (LVAD) market is categorized into ten notable segments which are based on product type, therapy, age group, indication, generation, durability, design, pulse type, end users, and distribution channel.
On the basis of therapy, the global left ventricular assist device (LVAD) market is segmented bridge-to-transplant (BTT) therapy, destination therapy, bridge-to-candidacy (BTC) therapy, bridge-to-recovery (BTR) therapy
On the basis of age group, the global left ventricular assist device (LVAD) market is segmented into adult and pediatric
On the basis of indication, the global left ventricular assist device (LVAD) market is segmented into congestive heart failure, congenital heart disease, myocarditis, cardiac arrest, familial arrhythymias and arrhythmic, cardiomyopathies, advanced heart failure and others
On the basis of generation, the global left ventricular assist device (LVAD) market is segmented into second-generation devices, third generation devices, first generation devices
On the basis of durability, the global left ventricular assist device (LVAD) market is segmented into long-term, intermediate-term, short-term
On the basis of design, the global left ventricular assist device (LVAD) market is segmented into axial and centrifugal
On the basis of pulse type, the global left ventricular assist device (LVAD) market is segmented into nonpulsatile and pulsatile
On the basis of end user, the global left ventricular assist device (LVAD) market is segmented into hospitals, cardiac cath laboratories, specialty clinics, others.
On the basis of distribution channel, the global left ventricular assist device (LVAD) market is segmented into direct tender, retail sales and others
Market Players
The key market players for global left ventricular assist device (LVAD) market are listed below:
Abbott
Evaheart, Inc
Saft (A Subsidiary of Total Energies)
ABIOMED
Berlin Heart
CorWave SA
Jarvik Heart, Inc
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.